News Recap: Zafgen Inc(NASDAQ:ZFGN), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Puma Biotechnology, Inc. (NYSE:PBYI)

Lakeway, NY — (MARKET NEWS CALL) — 12/22/2014—, an investment community with a special focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Zafgen Inc(NASDAQ:ZFGN), Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Puma Biotechnology, Inc. (NYSE:PBYI).

Zafgen Inc(NASDAQ:ZFGN)’s stock gained 7% to $25.84. The company on Dec. 15 announced that the Company has initiated a Phase 2b clinical trial with its lead product candidate, beloranib, in the treatment of patients with both severe obesity and type 2 diabetes.

Should Investors Buy ZFGN After The Recent Development? Find Out Here

The trial is a randomized, double-blind, placebo-controlled design in severely obese adults with a BMI between 30 and 60 kg/m2, and type 2 diabetes. The trial will aim to demonstrate weight loss over a 6 — 12 month period, along with improvements in glycemic control, and is expected to enroll 150 patients at approximately 15 sites across Australia.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX)’s stock climbed 6.63% to $25.89. The company on Dec. 4 announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b (FGFR2b) and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC). FPA144 is being developed initially as a monotherapy for refractory gastric cancer, a significant unmet medical need that may warrant an accelerated development and registration path.

Is FPRX Going To Rise or Fall After Today’s Price Action? Find Out Here

Puma Biotechnology, Inc. (NYSE:PBYI)’s stock jumped 6.06% to $221.30. Law Offices of Howard G. Smith on Dec. 19 announces that it is investigating potential claims on behalf of investors of Puma Biotechnology, Inc. (“Puma” or the “Company”) (PBYI) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company concerning Puma’s operations and financial prospects.

Can Traders Buy PBYI After The Solid Rally? Get Free Trend Analysis Here

The investigation is related to the Company’s December 2, 2014, announcement that its initial New Drug Application (NDA) filing with the U.S. Food and Drug Administration will now be for the early-stage breast cancer indication, and that Puma intends to delay its proposed timeline for filing its NDA until the first quarter of 2016.

About is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. also provides investors with trend analysis, detailed company profiles, and most importantly a much needed “informational edge” which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at


The assembled information disseminated by is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. does expect that investors will buy and sell securities based on information assembled and presented in PLEASE always do your own due diligence, and consult your financial advisor.